Discover
QuidelOrtho Science BYTES Podcast
QuidelOrtho Science BYTES Podcast
Author: QuidelOrtho
Subscribed: 7Played: 70Subscribe
Share
© Copyright 2023 All rights reserved.
Description
Today’s healthcare marketplace is more complex than ever. Labs today are faced with increasing regulatory and quality demands coupled with a shortage of skilled labor. QuidelOrtho is committed to helping labs meet these challenges head-on. Join us every month as we discuss the complex questions labs are facing every day.
52 Episodes
Reverse
Our 52nd episode of QuidelOrtho Science Bytes features George Wierschem, Senior Global Product Manager – informatics, discussing how informatics is transforming clinical labs. From streamlining workflows to strengthening cybersecurity, informatics helps labs turn data into decisions – faster, smarter and more securely.
George shares how modern platforms improve lab efficiency, ensure data integrity and support better patient outcomes through centralized access, automation and accountability.
About Our Speaker:
George Wierschem
Senior Global Product Manager for informatics at QuidelOrtho
George is a trained medical technologist with more than 30 years of laboratory experience. Over the first half of his career, George worked in a number of community-based hospitals progressing from bench technologist into leadership positions. In 2010, George entered the in vitro diagnostics industry, where he's been able to leverage his strong laboratory experience in consulting, product development and product management roles. Currently, George is helping to support legacy QuidelOrtho informatics platforms while also developing several innovative next-generation solutions. George holds an MBA with a healthcare administration specialization and is certified in Lean Six Sigma and change management.
This episode features Dr. Terry O’Neil, President and Medical Director of Urgent Care Pros, discussing why testing is essential when symptoms overlap during respiratory season. With conditions like strep, flu, RSV and COVID-19 often appearing similar at the outset, timely diagnostics provide clarity for both treatment and prevention.
Dr. O’Neil shares how rapid testing empowers urgent care providers to give patients clear answers, start appropriate treatment quickly, and reduce the risk of spreading illness to vulnerable family members and communities.
About Our Speaker:
Dr. O’Neil is a board-certified ER doctor and the president and medical director of Urgent Care Pros, a group of walk-in clinics providing fast and easy access to quality care. He has over 20 years of emergency room experience and a deep commitment to caring for patients. A graduate of Columbia University, Dr. O’Neil recognized the need for fast, efficient and specialized care in both urgent care and occupational health settings, which led him to establish Urgent Care Pros in January 2020. His approach reflects the mission of Urgent Care Pros, that is to provide unparalleled customer service and specialized health support in an affordable manner, ensuring patients receive the care they need when they need it most. Beyond his clinical work, Dr. O’Neil enjoys traveling, skiing and staying active through fitness, bringing the same energy and commitment to his personal life as he does to caring for his patients.
Our 50th episode of QuidelOrtho Science Bytes features Dr. Jonathan Temte, a leading public health expert, discussing how schools, families, and healthcare providers can stay ahead of respiratory illnesses this school year. As students return to classrooms, familiar viruses like flu, RSV, and COVID-19 often resurge.
Dr. Temte explains why symptoms alone can’t reliably distinguish between these illnesses and how rapid diagnostics are essential for early detection, accurate treatment, and preventing further spread.
About Our Speaker:
Dr. Temte joined the Department of Family Medicine and Community Health faculty at the University of Wisconsin-Madison in 1993. He is a professor of family medicine and community health and the Associate Dean for Public Health and Community Engagement for the University of Wisconsin School of Medicine and Public Health. Dr. Temte received his BA from Luther College, an MS in Biological Oceanography from Oregon State University, and his PhD in Zoology and Minor in Epidemiology from the University of Wisconsin. He pursued his medical training at the University of Wisconsin Medical School, where he received his MD. Dr. Temte also served as the Director of the Wisconsin Research and Education Network from 2000 to 2005. He chaired the American Academy of Family Physicians Commission on Science in 2008, the AAFP, and he currently chairs the Wisconsin Council on Immunization Practices. He also served as AAFP liaison to the Advisory Committee on Immunization Practices from 2004 to 2008, where he was appointed a voting member from 2008 to 2015 and served as chair from 2012 to 2015. Dr. Temte has also been active on pandemic influenza and bioterrorism working groups for the state of Wisconsin. In addition to his outstanding credentials, Dr. Temte's research interests include respiratory viruses, influenza, COVID-19, schools, and immunization policy.
In this episode, you'll hear a conversation with our own Vonda McAllister about the critical role of rapid diagnostic testing in helping prevent drug overdose deaths. Discover how early detection in emergency departments enables timely interventions when patients present with altered mental status or respiratory distress. The discussion explores the evolving landscape of substance abuse in 2025, including synthetic opioids like fentanyl, emerging threats like xylazine ("tranq") and the challenges of polydrug use, creating unpredictable and potentially fatal combinations.
About Our Speaker:
Vonda McAllister, Director of Global Product Management. Vonda's diagnostic experience spans from R&D and program management to marketing. Now a member of the Point of Care business unit, she previously managed the Triage™ portfolio of assays and the clinical labs team for North America. Vonda is currently focused on supporting the global regions with our PlGF tests, that is, placental growth factor, and toxicology assays, as well as expanding the Triage toxicology and women's health testing portfolio. She also serves as global leadership co-chair for the QuidelOrtho Women's Leadership Network.
In this episode, you'll hear a conversation with transfusion medicine expert Michelle Mullens about how blood donation underpins patient health and the critical role it plays in healthcare. Discover how donated blood is vital not only for trauma care, but also for cancer treatments, chronic illnesses like sickle cell disease, and a wide range of surgeries. The discussion explores the growing challenges of blood supply shortages, the importance of specialized blood types, and how automation in blood banks is helping labs maintain safety and efficiency despite staffing pressures. Learn how each donation makes a difference and why maintaining a robust blood supply is essential for patient care and safety.
About our speaker:
Michelle Mullens
Global Portfolio Marketing Manager for Transfusion Medicine, QuidelOrtho
Before beginning her career on the vendor side with QuidelOrtho, Michelle was a senior medical technologist at Baptist Health, serving in leadership roles in transfusion medicine and immunohematology for nearly 30 years. With QuidelOrtho, Michelle has served as a technical specialist, business development consultant and clinical science liaison before taking on her current role.
In this episode, you'll hear a conversation with three women's health experts about how early diagnostic testing is transforming care for heart disease, STIs, and preeclampsia. Discover how proactive screening empowers women, supports personalized care, and helps shift healthcare from reaction to prevention.
About Our Speakers:
Dr. Lindy Crimmins, Global Medical Affairs Manager. Lindy's clinical experience spans from emergency medicine to critical and primary care. Currently, she is responsible for providing medical support for the QuidelOrtho acute care menu throughout the product lifecycle. Lindy is passionate about education, testing guideline updates and assay utilization to drive improved patient-centered outcomes.
Dr. Rea Castro, Director of Medical Affairs. Rea is a seasoned medical professional with extensive experience in pharmaceutical clinical development, biotechnology and diagnostic product development across multiple therapeutic areas, including immunology, oncology and women's health. She is currently a cross-functional leader in medical affairs and is committed to advancing healthcare outcomes through innovative research, quality healthcare delivery and rigorous safety standards.
Vonda McAllister, Director of Global Product Management. Vonda's diagnostic experience spans from R&D and program management to marketing. Now a member of the Point of Care business unit, she previously managed the Triage™ portfolio of assays and the clinical labs team for North America. Vonda is currently focused on supporting the global regions with our PlGF tests, that is, placental growth factor, and toxicology assays, as well as expanding the Triage toxicology and women's health testing portfolio. She also serves as global leadership co-chair for the QuidelOrtho Women's Leadership Network.
In this episode, we spotlight the essential yet often-overlooked role of medical laboratory technologists – the backbone of today’s healthcare. With 70% of clinical decisions relying on lab results, these professionals face challenges including staffing shortages, rising diagnostic demands, burnout and low compensation. We explore what's driving the crisis and, more importantly, what can be done to solve it.
About Our Speaker:
Katy Marcum
Global Head of Clinical Labs Business Unit
QuidelOrtho
Katy is responsible for leading innovation and commercial success of the business unit worldwide, including strategic direction and solutions development for laboratory diagnostics. In her more than 13 years in the clinical laboratory and invitro diagnostics industry, Katy has served in corporate leadership roles and in the lab with top-tier hospitals, including specimen processing and registration, core lab generalists, and microbiology and serology.
This episode discusses the growing threat of sepsis, a life-threatening condition caused by the body's overwhelming response to an infection. It explores the connection between the rise in sepsis cases and the increasing problem of antibiotic resistance, highlighting the importance of effective diagnostic tools and antibiotic stewardship programs in combating this public health challenge.
About Our Speaker:
Dr. Mike Broyles
With more than 30 years of experience as a hospital pharmacy and laboratory director, Dr. Broyles is a leading expert on sepsis and the clinical use of drugs with a focus on antimicrobial stewardship. Prior to joining Thermo Fisher Scientific, Dr. Broyles was a consultant for over 25 years working with a large independent hospital network as pharmacy advisor chairman focused on developing and implementing hospital-wide clinical initiatives. Dr. Broyles has worked passionately throughout his career to define effective protocols and decision support processes in patient management and the use of diagnostic technology to help clinicians improve outcomes through better clinical care.
In this episode, we’ll discuss the importance of cardiac testing at the point of care with two renowned experts on the topic, doctors Martin Than and Paul Collinson. Both of our guests today have extensive experience on the front lines of patient care and have witnessed firsthand how point-of-care testing can save time and save lives.
About our speakers:
Doctor Martin Than currently holds several positions in the field, including consultant specialists and director of research for the emergency department at Christchurch Hospital in New Zealand. He has authored 187 peer-reviewed journal articles on emergency medicine, cardiac care and diagnostics. Doctor Than is recognized worldwide for his research on the rapid diagnosis of acute coronary syndrome.
Doctor Paul Collinson is presently a professor of cardiovascular biomarkers and consultant cardiologist at City Saint George's Medical School in London. Doctor Collinson has held clinical staff and university faculty positions in orthopedics, general family medicine, cardiology and pathology. He has published over 300 papers and review articles, 281 abstracts and 15 book chapters. Doctor Collinson has also been recognized numerous times for his research by the American Association of Clinical Chemists, including the Outstanding Research Award in point-of-care testing, as well as the high test award, now the IFCC Award for Lifetime Achievement and Cardiovascular biomarkers.
In this episode, we’ll explore how quality performance metrics are transforming clinical laboratory operations and why measuring the details – from accuracy to turnaround times – are essential for improving everything from test results to patient care.
About Our Speaker:
Johanna Miller, Global Product Manager for QuidelOrtho. Johanna brings a wealth of expertise working with laboratory metrics. She also has a strong background in data science, and she recently published a peer-reviewed article on a novel approach to leveraging big data to calculate Sigma metrics using input from real-world clinical laboratories. Johanna has also worked closely with lab teams to build the discipline to provide metrics they can use to improve their performance. She's passionate about helping lab staff achieve excellence through data and innovation, and today she'll share her insights on how metrics can help teams navigate challenges, prioritize improvements and ultimately deliver the best possible patient outcomes.
Rh disease remains a significant health challenge, particularly impacting expectant mothers and their newborns. In this episode of Science Bytes, Dr. Steven Spitalnik discusses the milestones in Rh disease treatment, the ongoing challenges and future opportunities to combat this condition.
About our Speaker
Dr Spitalnik, MD is a Professor in the Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons of Columbia University, and a member of the Medical Staff at New York Presbyterian/Columbia. He has authored over 250 publications and served as an investigator on ~30 grants and contracts including Principal investigator on ~20 of those grants. Additionally, he has sponsored more than 15 Training Grants. Dr. Spitalnik is a member of multiple professional societies, including the Association for the Advancement of Blood and Biotherapies (AABB) and the International Society for Blood Transfusion (ISBT). He has served on multiple committees within these organizations and was on the Board of Directors for the AABB. He has received multiple society awards and was elected to the Hall of Fame of the AABB Foundation (previously the National Blood Foundation). Dr. Spitalnik is the Founding Member and Executive Director of the Worldwide Initiative for Rh Disease Eradication (WIRhE).
The syphilis epidemic in the U.S. is a growing public health crisis, with rates increasing by 76% from 2018 to 2022. Syphilis is preventable and curable, but early detection is key—especially for pregnant women, where timely testing can prevent congenital syphilis.
Don’t miss this episode on the solutions to this growing epidemic.
About Our Speaker:
Dr. Lily Li is the Senior Director of Medical, Scientific & Clinical Affairs at QuidelOrtho. With a medical degree from Peking University and a PhD in Immunology from the University of Alberta, Dr. Li has guided the development of multiple infectious disease diagnostic tests at QuidelOrtho.
Did you know that women are 10 times more likely than men to develop a thyroid condition, yet often remain undiagnosed due to medical bias and lack of awareness? We often see women present themselves to an emergency department with health concerns that are brushed off as “stress” or “weight-related” versus conducting diagnostic testing to identify the root cause.
How can we address that?
Don’t miss this episode on how healthcare providers can address these types of biases including timeliness of diagnosis, screening practices, and interpretation of lab results to enhance the quality of care for women with thyroid conditions.
About our speaker
Jeff Houtz, Senior Global Product Manager
Jeff Houtz is the Senior Global Product Manager for QuidelOrtho covering thyroid and reproductive endocrine products. Jeff has 35 years of experience in research and development, product development, and medical education in a variety of disease states including reproductive and thyroid disorders. Providing accurate and meaningful diagnoses in furtherance of improved healthcare has always been a driver and motivator. Jeff has been instrumental in creating numerous CME and P.A.C.E.-accredited content for physicians, nurses, and laboratorians in the U.S. and Europe.
In addition to assay development Jeff is passionate about patient advocacy which is why he has worked closely with the Graves’ Disease and Thyroid Foundation and Thyroid Federation International. Jeff has also collaborated with LifeTime TV in support of programs on The Balancing Act and Access Health surrounding thyroid disease.
Jeff is also a family man married for 30 years with 2 wonderful kids.
The World Health Organization estimates 3.7 billion people under age 50 (67%) globally have herpes simplex virus type 1 (HSV-1) infection, the main cause of oral herpes, and 491 million people aged 15–49 (13%) worldwide have a herpes simplex virus type 2 (HSV-2) infection, the main cause of genital herpes. Although treatable, most HSV infections are often asymptomatic or unrecognized. Moreover, management of HSV infections is complicated by overlapping clinical presentation of unrelated herpesvirus infections, such as varicella-zoster virus (VZV), requiring differential diagnosis. Innovations in molecular diagnostics continue to play a critical role in the diagnosis and management of these diseases.
About Our Speaker:
Lori Henderson earned a bachelor’s degree in biology from Bucknell University. She began her career in the laboratory working on drug discovery and then transitioned into commercial roles within the biopharma and diagnostics sectors of the life science industry. Lori has direct experience in multiple disease and therapeutic areas and currently focuses on sexually transmitted diseases and women’s health. Within the molecular business unit at QuidelOrtho, Lori is responsible for identifying and helping drive the development of products to meet clinical and patient needs.
Sickle cell disease (SCD) patients are at risk of developing multiple complications from transfusions, including alloimmunization to red blood cell antigens, delayed hemolytic transfusion reactions and hyperhemolysis syndrome (HHS). While HHS is a rare complication of repeat blood transfusions in patients with SCD, clinicians and the laboratory have important roles in its detection and management.
In this podcast, Wally R. Smith, MD, the inaugural Florence Neal Cooper Smith Professor of Sickle Cell Disease at Virginia Commonwealth University shares insights to screening for and managing HHS.
About Our Speaker:
Wally R. Smith, MD, is an experienced implementation scientist and expert in clinical and health services research in sickle cell disease (SCD). He serves as Vice Chair for Research of the Division of General Internal Medicine at Virginia Commonwealth University (VCU) and was Scientific Director of the Center on Health Disparities at VCU. Dr. Smith has authored over 100 publications and served as an investigator on over 50 grants and contracts. He has been principal investigator on 26 federal or foundation-funded grants and contracts including: Pain in Sickle Cell Epidemiology Study (PiSCES), the largest and most detailed adult cohort that changed our understanding of SCD pain in adults and, since 2012, Start Healing in Patients with Hydroxyurea, the first-ever randomized controlled trial of implementation science in SCD.
Six Sigma is a popular way to measure quality. Sigma metrics have been adapted for the clinical laboratory by incorporating observed accuracy, precision and total error allowed (TEa). In vitro diagnostic (IVD) manufacturers have used Six Sigma to assess the quality of their assays using a small number of well-controlled systems to generate the data. QuidelOrtho has developed a novel approach to assess laboratory Sigma metrics for a broad range of assays using data from over 1,300 Vitros® instruments used in clinical labs.
In this podcast, Johanna Miller, data scientist at QuidelOrtho, discusses the value of using real-world data to perform Sigma metric studies and how a lab can use this information.
About Our Speaker:
Johanna Miller holds a bachelor's degree in biomedical engineering from the University of Rochester and a master's in product development and data science from the Rochester Institute of Technology. She spent 10 years developing expertise on Vitros systems and the data it generates, while working in product development. Currently, she focuses on developing new and interesting methods to use data at QuidelOrtho - specifically to bring insights directly to labs using Six Sigma quality scores.
Reference intervals (RIs) are a fundamental decision support tool used by clinicians and lab professionals to interpret laboratory reports and assess an individual’s health status. The establishment of reference intervals, however, can be challenging due to many physiological factors that influence their values and heterogeneities that inherently exist in populations.
In this podcast, Dr. Lindy Crimmins will provide a comprehensive explanation of the influencing factors and evolving methodology of RIs from how they are established to how they are advancing.
About Our Speaker:
Dr. Lindy Crimmins is a Manager of Medical Affairs at QuidelOrtho. She holds a Bachelor’s degree in Chemistry from the University of Wisconsin-Madison and a Medical Degree from the University of Illinois. Her clinical experience spanned from Emergency Medicine to critical care to primary care. Her time in the industry focused on clinical chemistry and point-of-care technical support prior to Medical and Scientific Affairs. Currently, she is responsible for providing medical support for QuidelOrtho’s acute care menu throughout the product lifecycle.
Each year 4.5 million lives are saved by blood transfusions thanks to blood donations. More than 118 million units of blood are donated worldwide every year but less than 10% of people who can donate blood will give. These repeat blood donors enjoy benefits of their own while providing their lifesaving gift. Donating blood burns 650 calories, reduces stress, provides an emotional lift and has physiological benefits.
In this podcast, Dr. Mark A. Levine shares the critical importance of blood donation and how repeat donors enjoy both emotional and physical health benefits.
About Our Speaker:
Dr. Levine is an award-winning physician and lecturer with interests in health professional education, the history of medicine and community empowerment. For 14 years, he served as Chief Medical Officer at the Centers for Medicare and Medicaid Services in Denver. Dr. Levine founded the Colorado Patient Safety Coalition and served as chair of the American Medical Association’s Council on Ethical & Judicial Affairs. He received his bachelor’s degree from Rutgers University and medical degree from Temple University School of Medicine.
Dr. Levine’s father, Dr. Phillip Levine, was a pioneering hematologist who joined Ortho Products in 1944 and his breakthrough discovery of Rh factor led to advancements in hemolytic disease of the newborn and safe blood transfusions saving countless lives.
Transfusion reactions are adverse events associated with the transfusion of whole blood or one of its components. They range in severity from minor to life-threatening and can occur during a transfusion, termed acute transfusion reactions, or days to weeks later, termed delayed transfusion reactions. Transfusion reactions may be difficult to diagnose as they can present with non-specific, often overlapping symptoms. The most common signs and symptoms include fever, chills, urticaria, and itching. Some symptoms may resolve with little or no treatment. However, respiratory distress, high fever, hypotension, and hemoglobinuria may indicate a more serious reaction. All cases of suspected reactions should prompt immediate discontinuation of the transfusion and notification of the blood bank and treating clinician. Learn in this podcast episode the evaluation and management of transfusion reactions and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients.
About our Speaker:
Dr. Aaron Tobian received his medical degrees from Case Western Reserve University. He is highly involved with the transfusion medicine community serving on the Association for the Advancement of Blood and Biotherapies' Board of Directors and is president-elect of the board. Dr. Tobian has authored more than 300 peer-reviewed articles in journals, including The New England Journal of Medicine, JAMA, Blood, and TRANSFUSION, and has been featured on BBC World Service, Today Show, National Public Radio, and USA Today. He is board certified in clinical pathology and blood banking/transfusion medicine and divides his time between research and clinical service.
Alloimmune hemolytic disease of the fetus and newborn (HDFN) may occur when a pregnant woman has an antibody against an antigen on the fetal red cells inherited from the father. Many antibodies to red blood cell antigens can cause HDFN, including those from the ABO, Rh, and other blood group systems. Women can develop antibodies either through previous pregnancy or transfusion.
Fatal consequences from this disorder have become rare with the appropriate use of immunoprophylaxis. However, to avoid the fatal consequences of this disorder, prompt recognition and treatment are vital. The risk for HDFN can be identified by testing the mother with an ABO group/Rh and antibody screen during the pregnancy. RhD HDFN can be prevented through passive anti-D administration to suppress the mother’s immune response against the fetal RhD antigen.
Some women may exhibit weak or discrepant results on RhD typing, or current results may differ from historical results. A common type of RhD variant is the weak D phenotype. Women with this phenotype have a weak expression of the RhD antigen and may present with variable RhD typing depending on the antisera or testing method used in the laboratory. Another type of RhD variant is the partial D phenotype where the RhD antigen is altered, potentially allowing an individual to form alloantibodies to the epitopes on RhD-positive red blood cells that are different than their own.
In this podcast episode, we will discuss the types of HDFN, the role that partial D groups, and the presence of anti-D as it relates to its prevalence, prognosis, and management.
About our Speaker:
Dr. Genghis Lopez is a Senior Scientist at the Australian Red Cross Lifeblood in Brisbane, Australia. Genghis received his Ph.D. degree from Griffith University, Australia. At Lifeblood, he worked at the Platelet and Granulocyte Reference Laboratory and Red Cell Reference Laboratory and is now part of the Transfusion Science research team that investigates complex red cell blood group variants. He has published several papers in Vox Sanguinis and Transfusion journals reporting novel red cell antigens, novel blood types, and red cell antibodies including several associated with hemolytic transfusion reactions or hemolytic disease of the fetus and the newborn.




